Hims & Hers Health (HIMS) will report its Q1 2026 earnings on May 11. The telehealth company heads into earnings with strong recent momentum, with HIMS stock gaining more than 37% over the past month. However, the stock is still down 17% year-to-date as investors weigh growing regulatory and competitive pressures tied to its weight-loss business. Here’s what Wall Street analysts are forecasting for the stock now.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
For context, Hims & Hers Health provides accessible healthcare products and services, including prescription medications, wellness products, and online medical consultations. Overall, analysts expect HIMS to post earnings per share of $0.03 in Q1, up from $0.02 a year ago. Meanwhile, analysts expect revenue to grow by over 5% year-over-year to $616.88 million.
Latest Analysts’ Views on HIMS Stock
Ahead of the earnings report, analysts remain moderately bullish on HIMS stock, with price targets ranging from $21 to $35.
Earlier this week, Deutsche Bank four-star-rated analyst George Hill lowered his price target on HIMS to $25 from $28 while maintaining a Hold rating on the stock. According to Hill, the company is facing pressure on multiple fronts, including new FDA regulations around compounding, litigation involving Novo Nordisk (NVO), and the end of the semaglutide shortage period that previously supported demand for compounded versions.
Before that, BofA’s analyst Allen Lutz raised his price target on Hims & Hers to $32 from $30 while keeping a Hold rating on the shares. The update followed Hims’ announcement that healthcare providers on its platform can now prescribe Zepbound vials, KwikPen, and Foundayo through LillyDirect, the pharmacy platform backed by Eli Lilly (LLY).
Lutz noted that the arrangement is not an exclusive partnership because any licensed healthcare provider can prescribe through LillyDirect. Still, he viewed the development as “neutral-to-positive,” saying it could help Hims build goodwill with Eli Lilly and support future partnerships with major pharmaceutical companies.
Who Are the Best Analysts Covering HIMS Stock?
Five-star-rated analyst Maria Ripps at Canaccord Genuity is the best analyst covering HIMS stock in the timeframe of three months. She has a success rate of 75% and an average return of 29.11% per trade. On TipRanks, Ripps is ranked #656 out of more than 12,000 analysts tracked.
Ripps has a Buy rating on HIMS with a $30 price target, implying an upside of about 11.6% from current levels. She believes the stock’s sharp decline over the past year does not fully reflect the company’s growing subscriber base, expanding weight-loss business, and long-term growth opportunity.
Ripps also stands out as the most profitable analyst covering HIMS stock over the timeframes of three months and one year.
Is HIMS Stock a Good Buy?
Overall, Wall Street analysts have a Moderate Buy consensus rating on HIMS stock based on five Buys and 10 Holds assigned in the last three months. The average HIMS stock price target of $28.0 implies an upside of 4.17% from the current trading level.
